Epitopea

Epitopea is a transatlantic cancer immunotherapy company founded in 2021 between Cambridge (UK), and Montreal (CA). This company originate from Claude Perreault and Pierre Thibault at the Institute for Research in Immunology and Cancer of the Université de Montréal. Epitopea is developing ready-to-use RNA-based immunotherapies for the treatment of difficult-to-cure cancers, by targeting a new class of antigens which had previously been unexploited and are widely shared by patients with the same type of tumor.

The company has discovered using its proprietary CryptoMapTM platform a vast library of novel antigens (TSA CryptigenTM), which draws on immunopetidomics, genomics and a bioinformatics pipeline to identify aberrantly expressed tumor-specific antigens (aeTSA).
Epitopea is backed by leading transatlantic life sciences investors, including Advent Life Sciences, CTI Life Sciences, Cambridge Innovation Capital, Fonds de Solidarité FTQ, Harrington Discovery Institute, Novateur Ventures and Investissement Québec. The company has raised over US$13 million.